MEDLINE/PubMed Journal Browser Search

Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

Title: Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
Author: Nural MS, Gokce E, Danaci M, Bayrak IK, Diren HB.
Journal: Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901.
Abstract:
OBJECTIVE: Gadobenate dimeglumine (Gd-BOPTA) is a liver-specific contrast agent also showing a distribution in the extracellular compartment which is recommended to be used at standard dose (0.05 mmol/kg) in magnetic resonance imaging (MRI) of liver lesions. However, its use at 0. 1mmol/kg is gradually increasing in recent clinical practice. Which dose should we use in routine MRI of liver lesions from now on? This study investigated the efficacy of Gd-BOPTA at a standard dose versus 0.1 mmol/kg dose in demonstrating diagnostic data in MRI of focal liver lesions. MATERIALS AND METHODS: The study included 47 patients with focal liver lesions. Twenty-two patients received standard dose and 25 patients received 0.1 mmol/kg dose Gd-BOPTA intravenously. MRI of both groups was carried out with T1-A FLASH-2D and T2-A TURBO spin echo before contrast injection and T1-A FLASH-2D sequences in dynamic and late phase (90th minute) after the contrast injection. The lesion conspicuity for each image was evaluated qualitatively. Liver signal to noise ratio (SNR), absolute lesion-liver contrast to noise ratio (CNR), mean lesion-liver CNR and contrast enhancement rate of the liver obtained from both groups were compared quantitatively. RESULTS: While liver contrast enhancement rate in the group receiving standard dose Gd-BOPTA were 41%+/-42 in the arterial phase, 66%+/-58 in the portal phase, 45%+/-45 in the venous phase and 42%+/-88 in the late phase, these values were 43%+/-59, 86%+/-73, 63%+/-75 and 61%+/-105, respectively, in the group receiving the dose of 0.1 mmol/kg. There were no statistically significant differences between the means of both groups. While the absolute lesion-liver CNR values were 18+/-15 precontrast, 22+/-18 in the arterial phase, 19+/-17 in the portal phase, 15+/-10 in the venous phase and 24+/-26 in the late phase in the group receiving the standard dose Gd-BOPTA, these values were 13+/-11, 18+/-15, 15+/-15, 13+/-13 and 19+/-21, respectively, in the group receiving the 0.1 mmol/kg dose. There were no statistically significant differences between the means of both groups (p>0.05). However, when the mean lesion-liver CNR values were compared, there was statistically significant difference between each arterial and portal phases of metastases in both groups (p<0.05). There was no statistical difference found in other lesions. When lesion conspicuity scores were compared, there were no significant differences between the two groups. CONCLUSION: In liver lesions, similar diagnostic data are obtained in dynamic and late phase MRI with either standard dose Gd-BOPTA or with a dose of 0.1 mmol/kg. Because there was a difference in only metastases in both groups, in oncological patients who are being investigated for liver metastasis, it is expedient to use a dose of 0.1 mmol/kg.

[Abstract] [Full Text] [Related] [New Search]